PBM lobby goes on the offensive

PBM Lobby Goes On the Offensive

PBM lobby goes on the offensive - The leading national pharmacy benefit manager (PBM) advocacy group has shifted from defense to offense, intensifying its lobbying campaigns to counter the pharmaceutical industry’s claims about high drug costs. This change comes in the wake of congressional action last winter, which included sweeping reforms targeting the PBM sector as part of a broader government funding package.

Industry Shift and Legislative Action

For years, the pharmaceutical sector has cast blame on PBMs, portraying them as key drivers of rising prescription drug prices. This criticism culminated in the passage of significant PBM reforms by Congress, which were embedded into a larger healthcare funding bill. The legislation marks a turning point, as it addresses longstanding grievances and reshapes the role of PBMs in the healthcare landscape.

David Marin, the CEO of the Pharmaceutical Care Management Association (PCMA), acknowledged in an interview that the PBM industry had long operated in the background, avoiding direct engagement with the broader issues of drug affordability. He emphasized the need for a more proactive approach, stating that the industry had been too passive in recent years.

With lawmakers now prioritizing affordability ahead of the upcoming midterm elections, PBMs are positioning themselves to reclaim their narrative. Marin noted that the PCMA had previously allowed pharmaceutical companies to define PBMs as the primary culprits in the cost crisis, which created an environment ripe for reform. “We want to be utterly transparent, we want to be fully understood,” Marin said, underscoring the group’s commitment to clarity.

Marin, who assumed his role in January, described how the PCMA had spent years enabling the pharmaceutical industry to frame PBMs as the enemy. This dynamic made the sector vulnerable to criticism, he argued. “I think it’s safe to say that for too long we were in a defensive posture, and that’s not what policymakers are looking for,” Marin explained. He credited the relentless efforts of Big Pharma for bringing attention to PBMs, calling it a necessary step in understanding the industry’s complexities.

Reforms and New Initiatives

The recent legislation has introduced several measures aimed at improving transparency and fairness within the PBM system. Among these changes are new reporting mandates that require PBMs to disclose more information about their operations. Additionally, the bill bans a practice known as “spread pricing,” where PBMs charge insurers more for medications than they reimburse pharmacies, effectively pocketing the difference.

Another critical reform separates PBMs’ compensation from the list prices of the drugs they select for coverage. This eliminates a potential conflict of interest, ensuring that PBMs are not incentivized to recommend costlier medications. These changes, according to critics, are essential for addressing the inefficiencies that have plagued the industry for years.

As part of this rebranding effort, the PCMA has launched a high-profile advertising campaign, its most ambitious to date. The campaign aims to educate the public and reshape perceptions of PBMs, highlighting their dual role in reducing costs and safeguarding patient care. “We want to be seen as partners in affordability and transparency,” Marin stated, emphasizing the need to align with policymakers’ goals.

Despite these efforts, the battle over drug pricing remains contentious. Pharmaceutical companies continue to accuse PBMs of inflating costs, while insurers and PBMs counter that the real issue lies with manufacturers. “No amount of message discipline can change the facts,” said Alex Schriver, a senior vice president at PhRMA, in a statement to The Hill. “Three PBMs control 80 percent of the market, routinely deny patients the medicines they’re prescribed, and ultimately decide what patients pay at the pharmacy counter.”

The Role of PBMs in Healthcare

PBMs function as intermediaries between insurers and drug manufacturers, managing prescription drug plans and negotiating rebates and discounts. Their responsibilities include determining drug prices, disbursing payments to pharmacies, and selecting which medications are covered under insurance plans. This position gives them significant influence over the cost patients face at the pharmacy counter.

Many PBMs are integrated into larger insurance companies, with the three largest entities—UnitedHealth Group’s Optum Rx, CVS Health’s Caremark, and Cigna’s Express Scripts—handling approximately 80 percent of all U.S. prescriptions. This concentration of power has made PBMs a focal point of the affordability debate, as their decisions directly impact healthcare spending.

Marin argued that the PCMA must now take the lead in redefining the industry’s image. He pointed out that pharmaceutical companies had effectively positioned PBMs as the villains, diverting attention from their own role in maintaining high drug prices. “We allowed others to define us, others who had a clear interest in diverting attention away from the role they play in keeping drug prices too high for too long,” Marin said. “They did it well. So I tip my hat to them, but we have to change that dynamic.”

The fight over drug pricing has been a multi-sided struggle, with each party accusing the others of contributing to the problem. While drugmakers point to PBMs and insurers as the main culprits, these groups argue that the pharmaceutical industry is ultimately responsible for high costs. Marin’s campaign seeks to bridge this gap by presenting PBMs as essential partners in the effort to reduce expenses and enhance patient access.

As the PCMA continues to push for rebranding, the focus remains on transparency and affordability. The group’s efforts are part of a broader strategy to ensure that PBMs are not only recognized for their contributions but also held accountable for their actions. With the new reforms in place, the PBM industry now faces the challenge of proving their value and reshaping their public image in the eyes of consumers and lawmakers alike.